Literature DB >> 25055070

Systemic lupus erythematosus activity and beta two microglobulin levels.

Thelma Larocca Skare1, Kellen Ferri2, Marcela Aimone Santos2.   

Abstract

CONTEXT AND
OBJECTIVE: Systemic lupus erythematosus (SLE) is an autoimmune disease with a cyclical clinical course. Evaluation of the clinical activity of this disease is important for choosing the correct treatment. The objective of this study was to analyze the value of beta-2 microglobulin (β2M) serum levels in determining SLE clinical activity. DESIGN AND
SETTING: Cross-sectional analytical study conducted at the rheumatology outpatient clinic of a private university hospital.
METHODS: 129 SLE patients were studied regarding disease activity using SLEDAI (SLE Disease Activity Index) and cumulative damage using SLICC ACR (SLE International Collaborating Clinics/American College of Rheumatology Damage Index for SLE). At the same time, the β2M serum level, ESR (erythrocyte sedimentation rate), anti-dsDNA (anti-double-stranded DNA) and C3 and C4 complement fractions were determined.
RESULTS: β2M levels correlated positively with SLEDAI (P = 0.02) and ESR (P = 0.0009) and negatively with C3 (P = 0.007). Patients who were positive for anti-dsDNA had higher β2M serum levels (P = 0.009).
CONCLUSION: β2M levels are elevated in SLE patients with active disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25055070     DOI: 10.1590/1516-3180.2014.1324703

Source DB:  PubMed          Journal:  Sao Paulo Med J        ISSN: 1516-3180            Impact factor:   1.044


  2 in total

1.  Regulatory effects of four ginsenoside monomers in humoral immunity of systemic lupus erythematosus.

Authors:  Xin Yu; Na Zhang; Wanfu Lin; Chen Wang; Wei Gu; Changquan Ling; Yinglu Feng; Yonghua Su
Journal:  Exp Ther Med       Date:  2017-12-18       Impact factor: 2.447

2.  Correlation between serum β2-microglobulin level and systemic lupus erythematosus disease activity: A PRISMA-compliant meta-analysis.

Authors:  Tao You; Xiaoyin Lin; Chunhong Zhang; Weilun Wang; Meihong Lei
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.